Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)
The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.
Breast Cancer
Clinical Benefit, defined as the development of at least one of the following stages and holding on for at least 6 month: Complete response, partial response or stable disease, Baseline, after 3, 6, 9 month
Tolerability, After 3, 6, 9 month (as per usual clinical practice)|Quality of Life, Baseline, after 3, 6, 9 month (as per usual clinical practice)|Performance status (Karnofsky Index), Baseline, after 3, 6, 9 month (as per usual clinical practice)
The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.